Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing
- PMID: 37379257
- DOI: 10.1021/acs.jmedchem.3c00794
Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing
Abstract
To facilitate subcutaneous dosing, biotherapeutics need to exhibit properties that enable high-concentration formulation and long-term stability in the formulation buffer. For antibody-drug conjugates (ADCs), the introduction of drug-linkers can lead to increased hydrophobicity and higher levels of aggregation, which are both detrimental to the properties required for subcutaneous dosing. Herein we show how the physicochemical properties of ADCs could be controlled through the drug-linker chemistry in combination with prodrug chemistry of the payload, and how optimization of these combinations could afford ADCs with significantly improved solution stability. Key to achieving this optimization is the use of an accelerated stress test performed in a minimal formulation buffer.
Similar articles
-
Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.J Control Release. 2021 Sep 10;337:431-447. doi: 10.1016/j.jconrel.2021.07.041. Epub 2021 Jul 27. J Control Release. 2021. PMID: 34329685
-
UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads.J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 1;1146:122075. doi: 10.1016/j.jchromb.2020.122075. Epub 2020 Mar 31. J Chromatogr B Analyt Technol Biomed Life Sci. 2020. PMID: 32361467
-
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Pharm Res. 2015 Nov;32(11):3541-71. doi: 10.1007/s11095-015-1704-4. Epub 2015 May 19. Pharm Res. 2015. PMID: 25986175 Review.
-
Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs.J Pharm Sci. 2020 May;109(5):1662-1672. doi: 10.1016/j.xphs.2020.01.029. Epub 2020 Feb 4. J Pharm Sci. 2020. PMID: 32027921
-
Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.MAbs. 2018 Apr;10(3):335-345. doi: 10.1080/19420862.2018.1433973. Epub 2018 Feb 20. MAbs. 2018. PMID: 29393747 Free PMC article. Review.
Cited by
-
Impact of dipeptide on ADC physicochemical properties and efficacy identifies Ala-Ala as the optimal dipeptide.RSC Med Chem. 2023 Nov 27;15(1):355-365. doi: 10.1039/d3md00473b. eCollection 2024 Jan 25. RSC Med Chem. 2023. PMID: 38283215 Free PMC article.
-
Recent Technological and Intellectual Property Trends in Antibody-Drug Conjugate Research.Pharmaceutics. 2024 Feb 3;16(2):221. doi: 10.3390/pharmaceutics16020221. Pharmaceutics. 2024. PMID: 38399275 Free PMC article. Review.
-
The medicinal chemistry evolution of antibody-drug conjugates.RSC Med Chem. 2024 Feb 28;15(3):809-831. doi: 10.1039/d3md00674c. eCollection 2024 Mar 20. RSC Med Chem. 2024. PMID: 38516594 Free PMC article. Review.
-
Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development.Antib Ther. 2025 Mar 9;8(2):99-110. doi: 10.1093/abt/tbaf005. eCollection 2025 Apr. Antib Ther. 2025. PMID: 40177644 Free PMC article. Review.
-
Minimising the payload solvent exposed hydrophobic surface area optimises the antibody-drug conjugate properties.RSC Med Chem. 2024 Jan 9;15(3):832-838. doi: 10.1039/d3md00540b. eCollection 2024 Mar 20. RSC Med Chem. 2024. PMID: 38516584 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources